Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SKB 410

Next Previous
Drug Profile

SKB 410

Alternative Names: MK-3120; SKB-410

Latest Information Update: 02 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Kelun Pharmaceutical Research Institute
  • Developer Merck Sharp & Dohme; Sichuan Kelun Pharmaceutical Research Institute
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 22 Apr 2026 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research, 2026 (AACR-2026)
  • 20 Jan 2026 Phase-I/II clinical trials in Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy, Inoperable/Unresectable) in Israel (IV) (NCT07232602)
  • 20 Jan 2026 Phase-I/II clinical trials in Urogenital cancer (Combination therapy, Metastatic disease, First-line therapy, Late-stage disease, Inoperable/Unresectable) in Israel (IV) (NCT07232602)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top